Literature DB >> 32420404

Infective Endocarditis Related to Unusual Microorganisms: A Prospective Population-Based Study.

Silvia Limonta1, Emmanuelle Cambau2, Marie-Line Erpelding3, Caroline Piau-Couapel4, François Goehringer5, Patrick Plésiat6, Matthieu Revest1, Véronique Vernet-Garnier7, Vincent Le Moing8, Bruno Hoen5, Xavier Duval9, Pierre Tattevin1.   

Abstract

BACKGROUND: Increased access to heart valves through early surgery and progress in molecular microbiology have reduced the proportion of infective endocarditis (IE) with no microbiological documentation and increased the proportion of IE associated with unusual microorganisms.
METHODS: We performed an ancillary study of a large prospective population-based survey on IE. Unusual-microorganism IE was defined as definite IE (Duke-Li criteria) due to microorganisms other than streptococci, staphylococci, or enterococci.
RESULTS: Of 471 cases of documented IE, 46 (9.8%) were due to unusal microorganisms; the following were involved in >1 case: Candida albicans (n = 4), Cutibacterium acnes (n = 4), Pseudomonas aeruginosa (n = 3), Cardiobacterium hominis (n = 3), and Coxiella burnetii (n = 2). Cases were documented with blood cultures (n = 37, 80.4%), heart valve polymerase chain reaction (PCR; n = 5), heart valve culture (n = 2), PCR on vertebral biopsy (n = 1), or serology (n = 1). As compared with IE due to staphylococci, streptococci, or enterococci (n = 420), IE due to unusual microorganisms occurred more frequently in patients with previously known heart disease (69.0% vs 44.3%; P = .002), prosthetic valve (40.5% vs 18.1%; P = .0006), longer duration of fever (mean, 35.1 ± 46.8 days vs 12.5 ± 17.8; P = .003), and who were more often nosocomial (38.1% vs 20.2%; P = .02).
CONCLUSIONS: In this population-based study, 9.8% of IE cases were due to unusual microorganisms, with a predominance of anaerobes, yeast, and gram-negative bacilli. As compared with IE related to staphylococci, streptococci, or enterococci, IE cases related to unusual microorganisms were associated with previously known heart disease, prosthetic valve, longer duration of fever, and nosocomial acquisition. TRIAL REGISTRATION: ORCID 0000-0003-3617-5411.
© The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

Entities:  

Keywords:  Candida sp; Cutibacterium acnes; HACEK; Pseudomonas aeruginosa; endocarditis

Year:  2020        PMID: 32420404      PMCID: PMC7216922          DOI: 10.1093/ofid/ofaa127

Source DB:  PubMed          Journal:  Open Forum Infect Dis        ISSN: 2328-8957            Impact factor:   3.835


Infective endocarditis (IE) is a life-threatening disease, mostly related to staphylococci, streptococci, and enterococci, altogether responsible for 80%–90% of IE cases in large cohort studies from Europe, North America, or Oceania [1, 2]. In the recent European guidelines [3], empirical treatment of IE in acutely ill patients targets these gram-positive cocci, although other microorganisms are found in 5%–10% of IE. Unusual microorganisms, defined as those “other than staphylococci, streptococci, and enterococci,” include (i) bacteria with documented tropism for cardiac valves, but accounting for a small proportion of IE cases (eg, HACEK group, Coxiella burnettii, Bartonella sp., Tropheryma whipplei); (ii) pathogens commonly encountered in other sites, but with very low propensity to affect cardiac valves (eg, Enterobacteriaceae, Pseudomonas spp., strict anaerobes). Unusual microorganisms have attracted limited attention to date and have mostly been reported as “miscellaneous” in cohort studies because of their heterogeneity and their low prevalence [4, 5]. However, better awareness of the risk factors for and the characteristics of these unusual microorganisms would be of interest, as some of them may not be susceptible to commonly used empiric antimicrobial regimens. We performed an ancillary study of a large prospective population-based survey on definite IE to better characterize IE due to unusual microorganisms.

METHODS

For this study, we analyzed the database created for the purpose of the French population-based epidemiological survey on IE in 2008, whose methods and results have been published elsewhere [6]. In brief, this survey was conducted in 7 regions of France (Paris, Lorraine, Rhône-Alpes, Franche-Comte, Marne, Ille-et-Vilaine, Languedoc-Roussillon), representing a population pool of 16 million inhabitants, 31.9% of the whole French population. All IE cases diagnosed in adults during the study period were reported. A standardized case report form (CRF) was prospectively filled out, and each case was validated by an adjudication committee, including screening for Duke-Li criteria, and confirmation of the causative pathogen. All IE cases that were not classified as definite according to the Duke-Li criteria [7] were excluded from further analysis. The following information was collected: sex, age, previously known heart disease, comorbidities (including diabetes mellitus, cancer, dialysis, and immunosuppressive therapy), Charlson comorbidity index [8], procedures and other risk factors for IE, date of first symptoms, date of hospital admission, IE diagnosis, and treatment, signs and symptoms of IE, echocardiography, microbiology, imaging studies, treatment, and outcome. Location of IE was determined by echocardiographic findings and could be updated by surgical findings. The mode of IE acquisition was categorized on the basis of 3 mutually exclusive classes: (i) injection drug use–associated IE; (ii) community-acquired IE; and (iii) health care–associated IE, which included nosocomial and non-nosocomial IE, according to prior definitions [6]. Community-acquired IE was considered in patients whose symptoms had started before or within 48 hours of admission and who did not meet criteria for health care–associated infection. Health care–associated IE was considered nosocomial if the first symptoms developed >48 hours after admission and up to 30 days after discharge from the hospital (up to 1 year after implantation of valve prostheses and up to 3 years for coagulase-negative staphylococci-infected intracardiac devices). Health care–associated IE was considered non-nosocomial if the patient had developed signs or symptoms consistent with IE before hospitalization and had undergone health care procedures (intravenous therapy, wound care, specialized nursing care at home, hemodialysis, or intravenous chemotherapy) outside a hospital within the 30 days before the onset of IE. Microbiological data included the total number of blood culture samples, the number of blood cultures with positive results, results of valve culture, results of serological tests, results of polymerase chain reaction (PCR) analysis of resected material, and causative microorganisms identified using classical culture methods, molecular biology, and/or serology. Unusual-microorganism IE was defined as IE due to microorganisms other than streptococci, staphylococci, or enterococci. For the comparison between IE due to unusual microorganisms and IE due to usual microorganisms, we excluded polymicrobial IE. The study was approved by an institutional review board (Comité de Protection des Personnes, Besançon, France). Patients were informed about the study but did not have to provide individual consent, in accordance with French legal standards. Quantitative variables were expressed as mean ± SD or as median and interquartile range (IQR). Qualitative variables were described as number (%). Continuous variables were compared using the Student test, and categorical variables were compared using the χ 2 or the Fisher exact test, as appropriate. The level of significance α was set at .05. All statistical analyses were performed using SAS 9.2 (SAS Institute, Cary, NC, USA).

RESULTS

From January 1 to December 31, 2008, 497 patients were diagnosed with definite IE, with 471 cases (94.8%) being microbiologically documented: streptococci and other Streptococcaceae, n = 188 (37.8%), staphylococci, n = 180 (36.2%), enterococci, n = 52 (10.5%), other microorganisms, n = 42 (8.5%), and polymicrobial, n = 9 (1.8%). Among the 9 polymicrobial IE, 4 included at least 1 unusual microorganism: Stenotrophomonas maltophilia and Candida pelliculosa (formerly Pichia anomala), Candida albicans and Candida glabrata, Bacillus cereus and Staphylococcus capitis, Haemophilus spp., and Streptococcus gordonii. The characteristics of the 42 cases of definite nonpolymicrobial IE involving unusual microorganisms are summarized in Table 1, and the list of these unusual microorganisms is presented in Table 2. The following species accounted for >1 case: Candida albicans (n = 4), Cutibacterium acnes (formerly Propionibacterium acnes, n = 4), Pseudomonas aeruginosa (n = 3), Cardiobacterium hominis (n = 3), and Coxiella burnetii (n = 2). Seven patients had HACEK IE due to C. hominis (n = 3), Haemophilus spp. (n = 3), and Aggregatibacter spp. (n = 1). Four patients had Enterobacteriaceae IE (Escherichia coli, Klebsiella pneumoniae, Serratia marcescens, Proteus mirabilis, 1 case each). Most cases were diagnosed with blood cultures (n = 37, 80.4%). The 9 cases of blood culture–negative IE were diagnosed by cardiac valve PCR (n = 5), valve culture (n = 2), PCR on vertebral biopsy (n = 1), and serology (n = 1).
Table 1. 

Characteristics of Infective Endocarditis due to Unusual Microorganisms (n = 42, Polymicrobial Cases Excluded)

Patients
Age, y62 (51–70)
Male sex32 (76.2)
Comorbidity(ies)21 (50.0)
Previously known heart disease29 (69.0)
Prosthetic valve17 (40.5)
Pacemaker or intracardiac defibrillator9 (21.4)
Location of infective endocarditis
Aortic16 (38.1)
Mitral13 (30.9)
Aortic and mitral5 (11.9)
Cardiac lesions
Vegetation32 (76.2)
Abscess6 (14.3)
Dehiscence6 (14.3)
Complications
Embolic events (extracerebral)11a (26.2)
Septic shock6 (14.3)
Spondylodiscitis or septic arthritis4 (9.5)
Treatment
Duration of anti-infective treatment, d45.5 (36.5–72)
Cardiac surgery19 (45.2)
Time between anti-infective treatment start and surgery, d4 (1.5–14)

Data are expressed as number (%) or median (interquartile range).

aNine splenic, 1 pulmonary, 1 peripheral.

Table 2. 

Unusual Microorganisms Documented by Culture, Serology, or PCR in Definite IE Cases (n = 46, Including 4 Polymicrobial Cases)

MicroorganismsaTotalBlood CultureValve or Other Site (Culture/PCR)
HACEK
 Aggregatibacter actinomycetemcomitans (i)110
 Cardiobacterium hominis (i)321 (valve PCR)
 Haemophilus spp. (i)220
 Haemophilus parainfluenzae (i)101 (valve PCR)
Gram-negative bacilli
 Acinetobacter ursingii (ii)110
 Campylobacter fetus (i)110
 Escherichia coli (i)110
 Francisella tularensis (ii)110
 Klebsiella pneumonia (i)111 (valve culture)
 Proteus mirabilis (i)110
 Pseudomonas aeruginosa (ii)330
 Serratia marcescens (i)110
 Stenotrophomonas maltophilia (ii)111
Gram-negative cocci
 Moraxella catarrhalis (i)110
 Neisseria elongata (i)110
Gram-positive bacilli
 Bacillus cereus (ii)101 (pacemaker culture)
 Corynebacterium jeikeium (i)110
 Corynebacterium mucifaciens (i)110
 Erysipelothrix rhusiopathiae (ii)110
 Gordonia bronchialis (i)110
 Lactobacillus rhamnosus (i)101 (PCR on vertebral biopsy)
 Lactobacillus spp. (i)222 (valve culture)
 Listeria monocytogenes (ii)110
Anaerobes
 Catabacter honkongensis (i)110
 Cutibacterium acnes (i)422 (valve culture)
 Veillonella spp. (i)110
Other bacteria
 Bartonella quintana (ii)101 (valve PCR)
 Coxiella burnetii (ii)2b01 (valve PCR)
 Tropheryma whipplei (ii)101 (valve PCR)
Yeasts
 Candida albicans (i)441 (valve culture)
 Candida parapsilosis (i)220
 Candida glabrata (i)110
 Candida spp. (i)110
 Candida pelliculosa (i)101 (valve culture)

Abbreviations: IE, infective endocarditis; PCR, polymerase chain reaction.

aMicroorganisms were categorized as (i) endogenous; (ii) exogenous (environment, zoonosis).

bIn 1 case, diagnosis relied on serology.

Characteristics of Infective Endocarditis due to Unusual Microorganisms (n = 42, Polymicrobial Cases Excluded) Data are expressed as number (%) or median (interquartile range). aNine splenic, 1 pulmonary, 1 peripheral. Unusual Microorganisms Documented by Culture, Serology, or PCR in Definite IE Cases (n = 46, Including 4 Polymicrobial Cases) Abbreviations: IE, infective endocarditis; PCR, polymerase chain reaction. aMicroorganisms were categorized as (i) endogenous; (ii) exogenous (environment, zoonosis). bIn 1 case, diagnosis relied on serology. The mean age of patients with nonpolymicrobial IE related to unusual microorganisms was 60.7 ± 14.2 years (median [IQR], 62 [51-70] years), and 32 patients (76.2%) were men. As compared with patients with nonpolymicrobial IE related to staphylococci, streptococci, or enterococci (Table 3), IE related to unusual microorganisms was more common in patients with previously known heart disease (69.0% vs 44.3%; P = .002), prosthetic valve (40.5% vs 18.1%; P = .0006), nosocomial IE (38.1% vs 20.2%; P = .02), and prolonged fever (mean ± SD, 35.1 ± 46.8 days vs 12.5 ± 17.8; P = .003). Comparison of staphylococci IE, streptococci/enterococci IE, and unusual-microorganism IE is presented in Supplementary Table 1.
Table 3. 

Comparison of Endocarditis due to Staphylococci, Streptococci, or Enterococci (n = 420) and Endocarditis Due to Unusual Microorganisms (n = 42), Polymicrobial Cases Excluded

Staphylococci, Streptococci, or Enterococci IE (n = 420)Unusual Microorganisms IE (n = 42) P Value
Patients’ characteristics
Age, y62.8 ± 16.060.7 ± 14.2.42
Male sex317 (75.5)32 (76.2).92
Charlson comorbidity index1.9 ± 2.22.3 ± 2.7.52
≥1 comorbidity196 (46.7)21 (50.0).68
Cardiac history
Previously known heart disease 186 (44.3)29 (69.0) .002
Prosthetic valve76 (18.1)17 (40.5) .0006
Intracardiac device (PM or ICD)53 (12.6)9 (21.4).11
Mode of acquisition .018
Community-acquired IE313 (73.6)26 (61.9)
Nosocomial IE83 (20.2)16 (38.1)
Health care–associated, non-nosocomial IE14 (3.4)0
Clinical and biological features
Time to IE diagnosis <4 d after admission200 (47.7)15 (35.7).14
Vegetation(s)375 (89.3)32 (76.2).13
Fever367 (87.8)32 (76.2).77
Fever duration, d12.5 ± 17.835.1 ± 46.8 .003
Outcome
Cardiac surgery182 (43.3)19 (45.2).81
In-hospital death101 (24.0)6 (14.3).15

Data are expressed as number (%) of patients or mean ± SD. In bold: P values < 0.05.

Abbreviations: ICD, implantable cardioverter defibrillator; IE, infective endocarditis; PM, pacemaker.

Comparison of Endocarditis due to Staphylococci, Streptococci, or Enterococci (n = 420) and Endocarditis Due to Unusual Microorganisms (n = 42), Polymicrobial Cases Excluded Data are expressed as number (%) of patients or mean ± SD. In bold: P values < 0.05. Abbreviations: ICD, implantable cardioverter defibrillator; IE, infective endocarditis; PM, pacemaker.

DISCUSSSION

To the best of our knowledge, this is the first population-based prospective study on IE due to unusual mircrooganisms. We found that 9.8% of documented IE involved unusual microorganisms, with C. albicans (n = 4), C. acnes (n = 4), P. aeruginosa (n = 3), C. hominis (n = 3), and C. burnetii (n = 2) being the most common unusual microorganisms. Previously known heart disease, prosthetic valve, nosocomial acquisition, and prolonged fever were more common in endocarditis due to unusual microorganisms, as compared with staphylococci, streptococci, or enterococci. In our study, most cases of IE related to unusual microorganisms were diagnosed by blood cultures (n = 37, 80.4%). Contrary to recent series of blood culture–negative endocarditis, largely dominated by 2 zoonotic pathogens, that is, C. burnettii and Bartonella sp. [5, 9–12], the spectrum of unusual microorganisms potentially responsible for IE appears broad, distributed in gram-negative bacilli (n = 11), gram-positive bacilli (n = 9), yeasts (n = 9), HACEK group (n = 7), anaerobes (n = 6), gram-negative cocci (n = 2), and others (n = 4). The proportion of IE related to strict anaerobes in our cohort (6/497, 1.2%) is in line with a recent prospective cohort in Spain [13], in which 0.9% of IE cases were due to strict anerobes, primarily C. acnes [14], as in our cohort. Likewise, the proportion of IE related to HACEK bacteria (7/497, 1.4%), Enterobacteriaceae (4/497, 0.8%), and P. aeruginosa (3/497, 0.6%) in our study is in the usual range for large cohort studies, such as the International Collaboration on Endocarditis (ICE), that is, 0.5%–3% of all IE cases [15-17]. Microbiological documentation of IE has dramatically improved over the last decades in developed countries, thanks to (i) the development of cardiac surgery during the acute phase of IE, which provides access to heart valves in up to half of patients with IE [6]; (ii) molecular biology, especially 16S rDNA PCR—the so-called “universal bacterial PCR”—which allows the identification of almost any bacteria encountered in IE, even when antibiotics have been initated before sampling [5, 11, 18]. These developments have reduced the proportion of IE with no microbiological documentation to <5% in contemporary cohort studies [6], while physicians and microbiologists are increasingly confronted with unexpected organisms identified by 16S rDNA on heart valves [18]. As about 20% of the unusual microorganisms were yeasts in our study, additional molecular tools targeting fungi, such as 18S and 28S rDNA PCR, may be of value. We found that unusual microorganisms are more commonly encountered in patients with previously known heart disease, prosthetic valve, or nosocomial IE. This reflects that specific predisposing conditions as well as nosocomial acquisition enlarge the spectrum of pathogens potentially associated with IE. Candida spp. and P. aeruginosa, both closely associated with nosocomial bloodstream infections, were among the top 4 pathogens identified in our study. Patients with IE related to unusual microorganisms had longer duration of fever compared with patients with staphylococci, streptococci, or enterococci IE. This may reflect (i) delayed diagnosis, due to longer time to positivity for blood cultures [19], or the need to wait for PCR on excised heart valves in patients with blood culture–negative IE; (ii) inactive empirical treatment, as most empirical treatment do not target unusual microorganisms; (iii) slower clinical response, even with appropriate anti-infective treatment, as may be expected with fastidious (ie, difficult-to-grow) microorganisms [4], or Candida spp. [20]. HACEK IE has been associated with prolonged fever and delayed diagnosis, as compared with IE related to other pathogens [15]. In our study, early diagnosis, as defined by time to diagnosis <4 days after hospital admission, tended to be more common for IE related to staphylococci, streptococci, or enterococci, as compared with IE related to unusual microorganisms (47.7% vs 35.7%; P = .14). Our study has limitations. First, as the study was performed in 1 country, during a single year, its findings may not be generalizable, given that the epidemiology of infectious diseases, including IE, may vary with time and geographical areas [21]. Second, due to the limited sample size, our study was not powered to describe rare causes of IE. In addition, the comparison of IE related to staphylococci, streptococci, or enterococci and unusual microorganisms could only be performed on a limited set of variables and probably missed significant risk factors. Third, unusual microorganisms responsible for IE were highly heterogeneous, merging IE cases classically associated with a protracted disease course, and good prognosis (eg, HACEK group or C. acnes IE) [4] with IE cases of dismal prognosis (eg, Enterobacteriaceae [17] or fungal IE [20]), which complicates the interpretation of our findings. Finally, as our cohort was restricted to definite IE according to modified Duke criteria, some cases of IE related to unusual microorganisms may have been missed, as blood culture criteria are more stringent for unusual microorganisms. However, this is, to our knowledge, the first population-based study on IE due to unusual microorganisms that has avoided the selection biases associated with studies originating from referral centers [22]. Our study provides original data on the characteristics of IE related to unusual microorganisms and risk factors. In conclusion, we found that 9.8% of documented IE involves unusual microorganisms, with a predominance of strict anaerobes, yeast, and gram-negative bacilli. As compared with IE related to staphylococci, streptococci, or enterococci, IE related to unusual microorganisms is associated with previously known heart disease, prosthetic valve, nosocomial acquisition, and longer duration of fever.

Supplementary Data

Supplementary materials are available at Open Forum Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author. Click here for additional data file.
  22 in total

1.  Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis.

Authors:  J S Li; D J Sexton; N Mick; R Nettles; V G Fowler; T Ryan; T Bashore; G R Corey
Journal:  Clin Infect Dis       Date:  2000-04-03       Impact factor: 9.079

2.  Emerging data indicating that extended incubation of blood cultures has little clinical value.

Authors:  Melvin P Weinstein
Journal:  Clin Infect Dis       Date:  2005-10-28       Impact factor: 9.079

3.  Revisiting the effect of referral bias on the clinical spectrum of infective endocarditis in adults.

Authors:  Z A Kanafani; S S Kanj; C H Cabell; E Cecchi; A de Oliveira Ramos; T Lejko-Zupanc; P A Pappas; H Giamerellou; D Gordon; C Michelet; P Muñoz; O Pachirat; G Peterson; R-S Tan; P Tattevin; V Thomas; A Wang; F Wiesbauer; D J Sexton
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-06-13       Impact factor: 3.267

4.  Comprehensive diagnostic strategy for blood culture-negative endocarditis: a prospective study of 819 new cases.

Authors:  Pierre-Edouard Fournier; Franck Thuny; Hervé Richet; Hubert Lepidi; Jean-Paul Casalta; Jean-Pierre Arzouni; Max Maurin; Marie Célard; Jean-Luc Mainardi; Thierry Caus; Frédéric Collart; Gilbert Habib; Didier Raoult
Journal:  Clin Infect Dis       Date:  2010-07-15       Impact factor: 9.079

Review 5.  Endocarditis due to rare and fastidious bacteria.

Authors:  P Brouqui; D Raoult
Journal:  Clin Microbiol Rev       Date:  2001-01       Impact factor: 26.132

6.  Endocarditis caused by anaerobic bacteria.

Authors:  M Kestler; P Muñoz; M Marín; M A Goenaga; P Idígoras Viedma; A de Alarcón; J A Lepe; D Sousa Regueiro; J M Bravo-Ferrer; M Pajarón; C Costas; M V García-López; C Hidalgo-Tenorio; M Moreno; E Bouza
Journal:  Anaerobe       Date:  2017-04-05       Impact factor: 3.331

7.  Propionibacterium acnes endocarditis: a case series.

Authors:  J M Banzon; S J Rehm; S M Gordon; S T Hussain; G B Pettersson; N K Shrestha
Journal:  Clin Microbiol Infect       Date:  2017-01-03       Impact factor: 8.067

Review 8.  Update on blood culture-negative endocarditis.

Authors:  P Tattevin; G Watt; M Revest; C Arvieux; P-E Fournier
Journal:  Med Mal Infect       Date:  2014-11-15       Impact factor: 2.152

Review 9.  HACEK endocarditis: state-of-the-art.

Authors:  Matthieu Revest; Gérald Egmann; Vincent Cattoir; Pierre Tattevin
Journal:  Expert Rev Anti Infect Ther       Date:  2016-03-28       Impact factor: 5.091

10.  Blood culture-negative endocarditis: Improving the diagnostic yield using new diagnostic tools.

Authors:  Pierre-Edouard Fournier; Frédérique Gouriet; Jean-Paul Casalta; Hubert Lepidi; Hervé Chaudet; Franck Thuny; Frédéric Collart; Gilbert Habib; Didier Raoult
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.817

View more
  2 in total

1.  A Rare Case of Successfully Treated Double Valve Infective Endocarditis Caused by Pseudomonas aeruginosa.

Authors:  Raluca Tomoaia; Alexandru Oprea; Irina Sandu; Vlad Danu; Dana Pop; Dumitru Zdrenghea; Alexandra Dădârlat-Pop; Ioan Alexandru Minciună; Ioana Maria Chețan; Nicoleta Cosmina Hada; Ruxandra Ștefana Beyer
Journal:  Int J Mol Sci       Date:  2022-09-22       Impact factor: 6.208

2.  Mycobacterium chimaera Genomics With Regard to Epidemiological and Clinical Investigations Conducted for an Open Chest Postsurgical Mycobacterium chimaera Infection Outbreak.

Authors:  Emmanuel Lecorche; Côme Daniau; Kevin La; Faiza Mougari; Hanaa Benmansour; Sylvain Kumanski; Jérôme Robert; Sandra Fournier; Guillaume Lebreton; Anne Carbonne; Emmanuelle Cambau
Journal:  Open Forum Infect Dis       Date:  2021-04-16       Impact factor: 3.835

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.